TARA

Protara Therapeutics, Inc. (TARA) is a biotechnology company operating in the healthcare sector with a market capitalization of $288.84 million and 28 employees. Financially, the company has reported negative profitability metrics, including gross margin, operating margin, and profit margin at 0.0%. Additionally, Protara Therapeutics has generated significant losses, with net income totaling -$52,901,000 and EBITDA reaching -$59,431,000 in the trailing twelve months (TTM). The company's cash balance is $132.67 million, while its debt stands at $3.66 million. The company's valuation metrics are as follows: a forward P/E ratio of -3.74, an EV/EBITDA of -1.32, and a price to book ratio of 1.57. Notably, the return on equity (ROE) is -49.4%, while the return on assets (ROA) is -31.3%. The debt to equity ratio is 2.76, indicating significant leverage, but also a relatively high current ratio of 13.69.